Financhill
Sell
31

ARAY Quote, Financials, Valuation and Earnings

Last price:
$1.91
Seasonality move :
-2.14%
Day range:
$1.79 - $1.87
52-week range:
$1.40 - $2.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.41x
P/B ratio:
3.99x
Volume:
708.7K
Avg. volume:
627K
1-year change:
-26.77%
Market cap:
$191.3M
Revenue:
$446.6M
EPS (TTM):
-$0.05

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ARAY
Accuray
$110.4M -$0.04 0.39% -8.33% $6.13
ABT
Abbott Laboratories
$11B $1.34 4.19% 52.11% $136.81
MASI
Masimo
$593.3M $1.43 -25.37% 192.38% $193.76
MMSI
Merit Medical Systems
$351.5M $0.83 8.97% 56.02% $118.20
RMD
ResMed
$1.3B $2.31 7.21% 15.65% $270.09
TMCI
Treace Medical Concepts
$67.2M -$0.04 1.88% -0.01% $11.29
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ARAY
Accuray
$1.86 $6.13 $191.3M -- $0.00 0% 0.41x
ABT
Abbott Laboratories
$126.34 $136.81 $219.1B 16.52x $0.59 1.77% 5.26x
MASI
Masimo
$165.82 $193.76 $8.9B 116.80x $0.00 0% 4.28x
MMSI
Merit Medical Systems
$101.67 $118.20 $6B 50.09x $0.00 0% 4.45x
RMD
ResMed
$219.70 $270.09 $32.3B 25.94x $0.53 0.94% 6.58x
TMCI
Treace Medical Concepts
$8.25 $11.29 $516.6M -- $0.00 0% 2.45x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ARAY
Accuray
78.56% 2.409 86.22% 0.78x
ABT
Abbott Laboratories
22.86% 0.603 7.72% 1.23x
MASI
Masimo
42.11% 1.378 8.64% 1.08x
MMSI
Merit Medical Systems
34.59% 1.540 12.84% 2.71x
RMD
ResMed
11.35% 0.169 2% 1.74x
TMCI
Treace Medical Concepts
32.07% 4.961 11.49% 3.34x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ARAY
Accuray
$41.9M $4.7M -2% -9.63% 5.26% $231K
ABT
Abbott Laboratories
$6B $1.9B 24.06% 32.63% 19.74% $2.1B
MASI
Masimo
$244.7M -$54.6M -14.23% -23.05% -58.55% $47.5M
MMSI
Merit Medical Systems
$173M $36.7M 5.83% 9.36% 11.58% $64.5M
RMD
ResMed
$751.3M $417.2M 21.74% 25.56% 32.54% $285.2M
TMCI
Treace Medical Concepts
$55.5M -$204K -32.41% -46.9% 1.18% -$7.3M

Accuray vs. Competitors

  • Which has Higher Returns ARAY or ABT?

    Abbott Laboratories has a net margin of 2.18% compared to Accuray's net margin of 84.1%. Accuray's return on equity of -9.63% beat Abbott Laboratories's return on equity of 32.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARAY
    Accuray
    36.06% $0.02 $223.4M
    ABT
    Abbott Laboratories
    54.97% $5.27 $62B
  • What do Analysts Say About ARAY or ABT?

    Accuray has a consensus price target of $6.13, signalling upside risk potential of 229.3%. On the other hand Abbott Laboratories has an analysts' consensus of $136.81 which suggests that it could grow by 8.28%. Given that Accuray has higher upside potential than Abbott Laboratories, analysts believe Accuray is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARAY
    Accuray
    3 0 0
    ABT
    Abbott Laboratories
    13 7 0
  • Is ARAY or ABT More Risky?

    Accuray has a beta of 1.460, which suggesting that the stock is 46.041% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.418%.

  • Which is a Better Dividend Stock ARAY or ABT?

    Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.77% to investors and pays a quarterly dividend of $0.59 per share. Accuray pays -- of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ARAY or ABT?

    Accuray quarterly revenues are $116.2M, which are smaller than Abbott Laboratories quarterly revenues of $11B. Accuray's net income of $2.5M is lower than Abbott Laboratories's net income of $9.2B. Notably, Accuray's price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 16.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.41x versus 5.26x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARAY
    Accuray
    0.41x -- $116.2M $2.5M
    ABT
    Abbott Laboratories
    5.26x 16.52x $11B $9.2B
  • Which has Higher Returns ARAY or MASI?

    Masimo has a net margin of 2.18% compared to Accuray's net margin of -58.2%. Accuray's return on equity of -9.63% beat Masimo's return on equity of -23.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARAY
    Accuray
    36.06% $0.02 $223.4M
    MASI
    Masimo
    40.74% -$6.52 $1.8B
  • What do Analysts Say About ARAY or MASI?

    Accuray has a consensus price target of $6.13, signalling upside risk potential of 229.3%. On the other hand Masimo has an analysts' consensus of $193.76 which suggests that it could grow by 16.85%. Given that Accuray has higher upside potential than Masimo, analysts believe Accuray is more attractive than Masimo.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARAY
    Accuray
    3 0 0
    MASI
    Masimo
    4 3 0
  • Is ARAY or MASI More Risky?

    Accuray has a beta of 1.460, which suggesting that the stock is 46.041% more volatile than S&P 500. In comparison Masimo has a beta of 1.035, suggesting its more volatile than the S&P 500 by 3.537%.

  • Which is a Better Dividend Stock ARAY or MASI?

    Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARAY or MASI?

    Accuray quarterly revenues are $116.2M, which are smaller than Masimo quarterly revenues of $600.7M. Accuray's net income of $2.5M is higher than Masimo's net income of -$349.6M. Notably, Accuray's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.41x versus 4.28x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARAY
    Accuray
    0.41x -- $116.2M $2.5M
    MASI
    Masimo
    4.28x 116.80x $600.7M -$349.6M
  • Which has Higher Returns ARAY or MMSI?

    Merit Medical Systems has a net margin of 2.18% compared to Accuray's net margin of 7.87%. Accuray's return on equity of -9.63% beat Merit Medical Systems's return on equity of 9.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARAY
    Accuray
    36.06% $0.02 $223.4M
    MMSI
    Merit Medical Systems
    48.71% $0.46 $2.1B
  • What do Analysts Say About ARAY or MMSI?

    Accuray has a consensus price target of $6.13, signalling upside risk potential of 229.3%. On the other hand Merit Medical Systems has an analysts' consensus of $118.20 which suggests that it could grow by 16.26%. Given that Accuray has higher upside potential than Merit Medical Systems, analysts believe Accuray is more attractive than Merit Medical Systems.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARAY
    Accuray
    3 0 0
    MMSI
    Merit Medical Systems
    5 1 0
  • Is ARAY or MMSI More Risky?

    Accuray has a beta of 1.460, which suggesting that the stock is 46.041% more volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.607%.

  • Which is a Better Dividend Stock ARAY or MMSI?

    Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARAY or MMSI?

    Accuray quarterly revenues are $116.2M, which are smaller than Merit Medical Systems quarterly revenues of $355.2M. Accuray's net income of $2.5M is lower than Merit Medical Systems's net income of $27.9M. Notably, Accuray's price-to-earnings ratio is -- while Merit Medical Systems's PE ratio is 50.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.41x versus 4.45x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARAY
    Accuray
    0.41x -- $116.2M $2.5M
    MMSI
    Merit Medical Systems
    4.45x 50.09x $355.2M $27.9M
  • Which has Higher Returns ARAY or RMD?

    ResMed has a net margin of 2.18% compared to Accuray's net margin of 26.88%. Accuray's return on equity of -9.63% beat ResMed's return on equity of 25.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARAY
    Accuray
    36.06% $0.02 $223.4M
    RMD
    ResMed
    58.6% $2.34 $5.9B
  • What do Analysts Say About ARAY or RMD?

    Accuray has a consensus price target of $6.13, signalling upside risk potential of 229.3%. On the other hand ResMed has an analysts' consensus of $270.09 which suggests that it could grow by 22.94%. Given that Accuray has higher upside potential than ResMed, analysts believe Accuray is more attractive than ResMed.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARAY
    Accuray
    3 0 0
    RMD
    ResMed
    8 6 1
  • Is ARAY or RMD More Risky?

    Accuray has a beta of 1.460, which suggesting that the stock is 46.041% more volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.

  • Which is a Better Dividend Stock ARAY or RMD?

    Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. Accuray pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ARAY or RMD?

    Accuray quarterly revenues are $116.2M, which are smaller than ResMed quarterly revenues of $1.3B. Accuray's net income of $2.5M is lower than ResMed's net income of $344.6M. Notably, Accuray's price-to-earnings ratio is -- while ResMed's PE ratio is 25.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.41x versus 6.58x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARAY
    Accuray
    0.41x -- $116.2M $2.5M
    RMD
    ResMed
    6.58x 25.94x $1.3B $344.6M
  • Which has Higher Returns ARAY or TMCI?

    Treace Medical Concepts has a net margin of 2.18% compared to Accuray's net margin of -0.73%. Accuray's return on equity of -9.63% beat Treace Medical Concepts's return on equity of -46.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARAY
    Accuray
    36.06% $0.02 $223.4M
    TMCI
    Treace Medical Concepts
    80.74% -$0.01 $166.2M
  • What do Analysts Say About ARAY or TMCI?

    Accuray has a consensus price target of $6.13, signalling upside risk potential of 229.3%. On the other hand Treace Medical Concepts has an analysts' consensus of $11.29 which suggests that it could grow by 36.8%. Given that Accuray has higher upside potential than Treace Medical Concepts, analysts believe Accuray is more attractive than Treace Medical Concepts.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARAY
    Accuray
    3 0 0
    TMCI
    Treace Medical Concepts
    2 5 0
  • Is ARAY or TMCI More Risky?

    Accuray has a beta of 1.460, which suggesting that the stock is 46.041% more volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ARAY or TMCI?

    Accuray has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray pays -- of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARAY or TMCI?

    Accuray quarterly revenues are $116.2M, which are larger than Treace Medical Concepts quarterly revenues of $68.7M. Accuray's net income of $2.5M is higher than Treace Medical Concepts's net income of -$501K. Notably, Accuray's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray is 0.41x versus 2.45x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARAY
    Accuray
    0.41x -- $116.2M $2.5M
    TMCI
    Treace Medical Concepts
    2.45x -- $68.7M -$501K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Progressive Stock Go Down?
Why Did Progressive Stock Go Down?

Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…

Why Did StoneCo Stock Go Up So Much?
Why Did StoneCo Stock Go Up So Much?

Brazilian fintech company StoneCo (NASDAQ:STNE) has been on a tear…

Is Tenable Stock a Buy, Sell or Hold?
Is Tenable Stock a Buy, Sell or Hold?

Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…

Stock Ideas

Buy
55
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 36x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Sell
50
RGC alert for Mar 24

Regencell Bioscience Holdings [RGC] is down 28.36% over the past day.

Buy
54
TNXP alert for Mar 24

Tonix Pharmaceuticals Holding [TNXP] is up 32.39% over the past day.

Sell
36
VMI alert for Mar 24

Valmont Industries [VMI] is up 4.67% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock